Biostax Corp (BTAX)

[la_trader]

IMUN INCLUDED IN TOP-TIER RESEARCH PAPER ALONGSIDE MAJOR INDUSTRY PLAYERS. (updated re-post, worth another mention)

"Global CAR T Cell Therapy Market 2016-2026: The Most Hot Topic Discussed Among Oncologists Throughout the Globe"

Can you say, "IMUN is an undervalued stock"? :D

Huge, unprecedented recognition for IMUN, this is a top tier analyst research paper used by hedge funds and institutions in determining new stock portfolio allocations in a given sector.

Of the bunch, IMUN is the most unrecognized and undervalued player. The best one to own IMO. These reports don't contain hype or fluff just hard data and resultant analyst research opinion.

Now if only IMUN would DO SOME REAL PR on this as well as present/upcoming events (REGULARLY!), we would easily see a .06-.10 stock price (normal level). The retail investing public needs to know IMUN is relevant to the other listed big names in the report and a key player in the immune-related therapy / drug sector.

Right now, the only folks who "know" are us, insiders and the horn rimmed glasses research analysts...

News link, large synopsis and overview of report content, PR contact info:
https://www.prnewswire.com/news-releases/global-car-t-cell-therapy-market-2016-2026-the-most-hot-topic-discussed-among-oncologists-throughout-the-globe-300666356.html

Purchase the report and view summary:
https://www.researchandmarkets.com/research/gtmk22/global_car_t_cell?w=5

LIST OF COMPARATIVE COMPANIES IN THE 2018-2026 FORECAST REPORT

Bellicum Pharmaceuticals, Inc.
Celgene Corporation.
Cellectis.
Eureka Therapeutics
Immune Therapeutics
Juno Therapeutics
Kite Pharma
Novartis AG
Sorrento Therapeutics

-----------------------
Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]
----------------------